Industry Advisors

Naomi Fried, Ph.D.

Dr Fried, a national thought leader on healthcare innovation, is founder and CEO of Health Innovation Strategies. Dr Fried was previously Biogen’s first Vice President of Innovation and External Partnerships. Prior to Biogen, she was the first Chief Innovation Officer at Boston Children’s Hospital (BCH) where she oversaw the FastTrack Innovation in Technology Program which developed novel clinical software solutions and mobile apps. She also initiated and led development of BCH’s telehealth strategy. Prior to BCH, Dr Fried was Vice President of Innovation and Advanced Technology in Kaiser Permanente’s (KP) Program Offices where she led an effort to identify and assess emerging health care technologies and formed KP’s Telehealth working group.

Joseph Kvedar, M.D.

Dr Kvedar is recognised globally for leadership and vision in the field of digital health and has authored over 100 publications on the subject. He is currently Vice President, Connected Health at Partners HealthCare. Under Dr Kvedar’s two decades of leadership, Partners Connected Health has launched a number of innovative mobile health programs, virtual care initiatives and clinical research programs for the more than 1.5 million patients served at Partners HealthCare-affiliated hospitals. He is the author of The New Mobile Age: How Technology Will Extend the Healthspan and Optimize the Lifespan (2017) and The Internet of Healthy Things (2015).

Scientific Advisors

Udantha Abeyratne, Ph.D.

Dr Abeyratne is an Associate Professor of Biomedical Engineering at The University of Queensland and inventor of ResApp’s platform technology. Dr Abeyratne has over 17 years’ experience in sound-based diagnosis of disease and 25 years’ experience in medical instrumentation and signal processing. His work has received funding from the Bill and Melinda Gates Foundation, the Australian Research Council, the Princess Alexandra Hospital Foundation, The University of Queensland and UniQuest Pty Ltd. In 2016, Dr Abeyratne was recognised as one of Australia’s Most Innovative Engineers by Engineers Australia, the leading body for engineering in Australia.

Paul Porter, M.B.B.S., F.R.A.C.P.

Dr Porter is a Consultant Paediatrician with subspecialty qualifications in Paediatric Emergency Medicine and General Paediatrics. Dr Porter has appointments at both Princess Margaret Hospital for Children and Joondalup Health Campus. He is also a Clinical Lecturer in Paediatrics at the University of Western Australia and a member of the Clinical Senate of Western Australia.

Philip Currie, M.B.B.S., F.R.A.C.P., M.B.A.

Dr Currie is a cardiologist with more than 35 years in cardiology both in the United States and in Australia with extensive experience in medical research, clinical cardiology and business. Dr Currie completed his medical residency and cardiology fellowship at the Alfred Hospital in Melbourne, followed by cardiology fellowship and staff cardiologist appointment at the Mayo Clinic. Dr Currie was a staff cardiologist for three years at the Cleveland Clinic and then Director of Echocardiography at the Michigan Heart and Vascular Institute for eight years. Dr Currie has been a Principal Investigator on multiple clinical studies at the Alfred Hospital, the Mayo Clinic and the Cleveland Clinic and was a co-investigator on the high-profile multi-centre international clinical trials, CAPRICORN and SERVE-HF. He received his medical degree from Monash University and holds an MBA from the University of Michigan.

Scott Claxton, M.B.B.S., F.R.A.C.P.

Dr Claxton is a Consultant Respiratory and Sleep Physician with GenesisCare Sleep and Respiratory and Joondalup health Campus. Dr Claxton’s work is equally divided between sleep disorders and general lung diseases, including asthma, pneumonia, smoking related lung disease and lung cancer. Dr Claxton completed his undergraduate medical training at the University of Tasmania and his advanced training in respiratory medicine at Royal Perth Hospital and Sir Charles Gairdner Hospital.

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.